Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/230195
COMPARTIR / EXPORTAR:
SHARE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Gliotoxin, a new candidate against methicillin-resistant Staphylococcus aureus showing synergistic effect with classical antimicrobial drugs in Caenorhabditis elegans infection model |
Otros títulos: | Gliotoxina, un nuevo candidato contra Staphylococcus aureus resistente a meticilina que muestra un efecto sinérgico con fármacos antimicrobianos en el modelo de infección Caenorhabditis elegans | Autor: | Esteban, Patricia CSIC; Redrado, Sergio CSIC; Comas, Laura CSIC ORCID; Seral, Cristina; Pardo, Julián; Arias, Maykel CSIC ORCID; Gálvez Buerba, Eva Mª CSIC ORCID | Palabras clave: | Gliotoxin Methicillin-resistant Staphylococcus aureus (MRSA) Antimicrobial resistance Aspergillus spp Antimicrobial drugs |
Fecha de publicación: | 18-abr-2020 | Citación: | 30th ECCIMD (2020) | Resumen: | [Background] Multidrug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) is among the major causes of hospital-acquired and community infections, and pose a challenge to the human health care system.
Therefore, it is important to find new drugs that show activity against these bacteria, both in monotherapy and in combination with other antimicrobial drugs. Gliotoxin is a mycotoxin produced by Aspergillus fumigatus and other fungi of the Aspergillus
genus. Some evidence suggests that gliotoxin shows antimicrobial activity, especially against S. aureus.
This work aims to evaluate the antibiotic efficacy of gliotoxin as monotherapy or in combination with other therapeutic against MRSA in vitro and in vivo using a C. elegans infection model. [Materials/methods] MRSA ATCC700699 sensitivity against gliotoxin was analysed by different methods: disc diffusion, time-mortality curves, microdilution assays. The synergistic effects of gliotoxin with others anti-staphylococcal drugs (vancomycin, fusidic acid and linezolid) were tested by a checkerboard assay. Transformed synchronized C. elegans L4 worms were infected with MRSA. The culture was supplemented separately with gliotoxin, vancomycin or its combination to different concentrations. The survival rate of C. elegans was scored manually every 12h for 4 days. [Results] Sensitivity analysis of MRSA against gliotoxin showed that gliotoxin has a potent antimicrobial activity (MIC = 2 μg/ml). In addition, synergistic activity was observed, when the gliotoxin was combined with vancomycin and fusidic acid, using checkerboard and time-kill assays. This synergistic effect was confirmed by CalcuSyn software (CI = 0.15 for 1 μg/ml of gliotoxin combined with 2 μg/ml of vancomycin). The in vivo study of S. aureus infection in a C. elegans model showed that combined treatment of vancomycin with gliotoxin increased 70% in survival rate of the MRSA-infected worms. [Conclusions] Our results suggest that gliotoxin is effective against MRSA strains indicating their potential use as a new drug against MRSA infections. |
Descripción: | Abstract of the work presented at the 30th ECCMID 2020, European Congress of Clinical Microbiology and Infectious Diseases, organized by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID).-- www.eccmid.org .-- www.escmid.org.-- Abstract 6144. | URI: | http://hdl.handle.net/10261/230195 |
Aparece en las colecciones: | (ICB) Comunicaciones congresos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
30th ECCIMD_6144.pdf | Abstract | 70,07 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
Page view(s)
120
checked on 23-abr-2024
Download(s)
25
checked on 23-abr-2024
Google ScholarTM
Check
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.